James Stevenson, M.D.

Thoracic Medical Oncologist

Dr. James Stevenson is a board-certified medical oncologist. He specializes in treating mesothelioma, lung cancer and other chest cancers. He currently sees patients at the Cleveland Clinic in Cleveland, Ohio.

Dr. Stevenson completed his undergraduate studies at the University of Notre Dame. He then earned his medical degree from Thomas Jefferson University in Philadelphia, Pennsylvania. His additional medical training includes:

• An internal medicine internship at Shands Medical Center in Gainesville, Florida
• An internal medicine residency at Thomas Jefferson University Hospital
• A hematology and medical oncology fellowship at Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital

For more than 20 years, Dr. Stevenson has contributed to mesothelioma research and treatment. At the Cleveland Clinic, he treats patients with mesothelioma, lung cancer and other rare cancers. His contributions to research and clinical trials have been significant for advancing mesothelioma care.

Dr. Stevenson and doctors at the Cleveland Clinic use a multidisciplinary approach to treating mesothelioma. This approach brings together specialists from various medical disciplines to treat mesothelioma patients.

Dr. Stevenson has contributed to the National Comprehensive Cancer Network’s (NCCN) guidelines. He has provided his expertise on the NCCN Clinical Guidelines for non-small cell lung cancer and pleural and peritoneal mesothelioma.

For Mesothelioma.com, Dr. Stevenson provides his medical expertise to the editorial team. He helps ensure the accuracy of medical content.

Selected Publications

Mesothelioma: peritoneal, version 2. 2023, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023 Sep;21(9):961–79.

Hsr22-166: patient demographic and socioeconomic differences in non-small cell and small cell lung cancers: impact on outcomes. A national cancer database analysis. Journal of the National Comprehensive Cancer Network. 2022 Mar 31;20(3.5):HSR22-HSR22-166.

Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer. 2019 Apr;130:59–66.

The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma. Onco Targets Ther. 2016;9:7247–52.

Current issues in malignant pleural mesothelioma evaluation and management. Oncologist. 2014 Sep;19(9):975–84.